Transaction #2544 · Form 4 · 0001193125-25-251983
Q32 Bio Inc. · Stock award · Stock Option (Right to Buy)
Q32 Bio Inc. · Transacted October 23, 2025 · Filed October 27, 2025
What does this filing report?
An SEC Form 4 filing for Q32 Bio Inc. records a stock award involving Stock Option (Right to Buy) on October 23, 2025. The reported quantity was 53,521. The filing date is October 27, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Q32 Bio Inc.
- Company CIK
- 0001661998
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 53,521
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 53,521
- Ownership description
- Not reported
- SEC acceptance time
- Oct 27, 2025, 9:17 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- GRAYZEL DAVID S. ↗
Director
CIK 0001732786
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 53,521
- Conversion / exercise price
- 2.8
- Exercise date
- Not reported
- Expiration date
- October 22, 2035
Filing footnotes & remarks
- F1
- The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
- F2
- This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.